Exercise and Acarbose in Type 2 Diabetes
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Acarbose
Exercise
Exercise + Acarbose
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria: Men and women, diagnosis of type 2 diabetes established since at least three months, treatment with diet or maximum one oral anti-diabetic drug, GHb < 8.5 %, age 45 - 60 years, BMI 25 - 30 kg/m2, no participation in any regular exercise program.
-
Exclusion Criteria: Unable to perform exercise, significant GI-disease, severe heart-disease, renal failure
-
Sites / Locations
- Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Experimental
Arm Label
Acarbose
Exercise
Exercise + Acarbose
Arm Description
Outcomes
Primary Outcome Measures
Glycemic control
Glycated A1c
Secondary Outcome Measures
Full Information
NCT ID
NCT01244971
First Posted
November 19, 2010
Last Updated
November 19, 2010
Sponsor
Karolinska Institutet
Collaborators
The Swedish Research Council, Bayer
1. Study Identification
Unique Protocol Identification Number
NCT01244971
Brief Title
Exercise and Acarbose in Type 2 Diabetes
Official Title
Effect of Exercise Training - Alone or in Combination With Acarbose - on Clinical and Metabolic Factors, and Studies of Cellular and Moleculargenetic Factors, in Type 2 Diabetes.
Study Type
Interventional
2. Study Status
Record Verification Date
December 2003
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
June 2004 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Karolinska Institutet
Collaborators
The Swedish Research Council, Bayer
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to investigate the impact of exercise training, Acarbose, and the combination of exercise and Acarbose on glycemic control, body composition, insulin sensitivity and other cardiovascular risk markers in type 2 diabetes. Further, muscle biopsies will be obtain to study gene expression. Our hypothesis is that the combination therapy will be superior to monotherapy with exercise or Acarbose.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Acarbose
Arm Type
Active Comparator
Arm Title
Exercise
Arm Type
Active Comparator
Arm Title
Exercise + Acarbose
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Acarbose
Intervention Description
100mg, 3 times daily
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
Moderate combined exercise, 50 minutes 3 times per week
Intervention Type
Other
Intervention Name(s)
Exercise + Acarbose
Intervention Description
See respective monotherapy description
Primary Outcome Measure Information:
Title
Glycemic control
Description
Glycated A1c
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
60 Years
Eligibility Criteria
Inclusion Criteria: Men and women, diagnosis of type 2 diabetes established since at least three months, treatment with diet or maximum one oral anti-diabetic drug, GHb < 8.5 %, age 45 - 60 years, BMI 25 - 30 kg/m2, no participation in any regular exercise program.
-
Exclusion Criteria: Unable to perform exercise, significant GI-disease, severe heart-disease, renal failure
-
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suad Efendic, Professor
Organizational Affiliation
Dpt of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Official's Role
Study Chair
Facility Information:
Facility Name
Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital
City
Stockholm
ZIP/Postal Code
17176
Country
Sweden
12. IPD Sharing Statement
Citations:
PubMed Identifier
16801564
Citation
Wagner H, Degerblad M, Thorell A, Nygren J, Stahle A, Kuhl J, Brismar TB, Ohrvik J, Efendic S, Bavenholm PN. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care. 2006 Jul;29(7):1471-7. doi: 10.2337/dc05-2513.
Results Reference
result
Learn more about this trial
Exercise and Acarbose in Type 2 Diabetes
We'll reach out to this number within 24 hrs